Introduction
An elevated homocysteine level or hyperhomocysteinemia was first reported to be associated with cardiovascular disease (CVD) in patients with homocystinuria, a group of inborn errors in metabolism leading to severely elevated homocysteine levels [1] . Based on the clinical and pathological findings in these patients, McCully in 1969 [2] proposed the homocysteine theory for atherosclerosis, which suggested that moderate elevation in homocysteine is also a CVD risk factor. In 1976, Wilcken and Wilcken [3] found that patients with coronary artery disease (CAD) had an abnormal homocysteine metabolism, and in the following 15 years, retrospective case--eontrol studies have shown that homocysteine is associated with occlusive disease in the coronary, cerebral and peripheral vessels and with venous thrombosis [4] [5] . In 1995, Bousheyetal.
[6] published a meta-analysis based on results from 27 studies which convincingly showed that total homocysteine (tHcy) is an independent, graded risk factor for CVD. Since then, there has been an increasing number of studies investigating tHey as a risk factor [7--] . The majority support the conclusions of Boushey et at. but also emphasize thrombogeniciry and interactive effects as consequential traits of elevated tHcy.
Total homocysteine as an interactive factor provoking the acute event
It has frequently been suggested that moderate hyperhomocysteinemia promotes atherosclerosis and acts independently of conventional risk factors [6] . Two papers challenge this view [8--,9--].
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The European COMAC project on homocysteine and vascular disease [8--] is a multi-centre case--eontrol study comprising 750 patients with confirmed CVD and 800 control individuals. This study showed that an increased tHcy level confers an independent and graded risk of CVD of similar strength to that of smoking or hyperlipidemia. A novel finding was that hyperhomocysteinemia interacts with several conventional risk factors, in particular smoking and hypertension, thereby markedly enhancing their effect [8--].
The second article describes a Norwegian prospective study on tHey as a predictor of mortality in 587 CAD patients who underwent coronary angiography in 1991-1992 [9--]. The tHcy level measured at the time of the angiography was significantly associated with 0957-9672 © 1998 Lippincott Williams &Wilkins 533 a previous history of myocardial infarction but, surprisingly, it was only weakly associated with the extent of coronary stenosis. Mter 5 years, 11% had died, but the mortality ratio showed a strong and dose-dependent relation with tHey. In patients with a tHey <9 Ilmol/I, only 4% had died compared with nearly 27% in those with a tHey~20 Ilmol/l. Furthermore, high tHey was a stronger predictor of mortality than conventional risk factors, including high cholesterol, elevated lipoprotein (a), and hypertension, and actually equaled low ventricular ejection fraction and reduced renal function.
The COMAC study emphasized that an elevated tHey level should not be evaluated independently of other risk factors, while the Norwegian mortality study suggested that a high tHey level causes an acute event rather than atherosclerosis, but both studies indicate that an elevated tHey level is particularly important in patients with high CVD risk. , and is also associated with decreased risk of colorectal cancer [28, 29] . On the other hand, it may promote CVD risk by interacting with certain genetic traits [30] , as demonstrated for the factor V Leiden mutation in some [31] but not all [32] populations.
The C677T MTHFR polymorphism, cardiovascular disease and longevity
Conceivably, hyperhomocysteinemia caused by the TT genotype may have a different association with CVD than elevated tHey which is a result of other causes. The COMAC study demonstrated that hyperhomocysteinemia in TT individuals is associated with less CVD risk than a similar tHey elevation in CC/CT individuals [Meleady et al. (1998) , unpublished observations]. This unexpected observation was explained when the prevalence of conventional risk factors was compared in TT and CC/CT individuals with tHey~15 Ilmol/l. The hyperhomocysteinemic TT individuals had a relatively low CVD risk profile, and the high tHey level was attributed to MTHFR genotype in combination with low vitamin status. In contrast, the hyperhomocystcinemic CT/CC individuals had a high prevalence of conventional risk factors. The data may indicate that hyperhomocysteinemia associated with TT genotype is less harmful than hyperhomocysteinemia which is accompanied by a high risk factor level. This corroborates the powerful interactive effects of high tHey described in the COMAC report we]. In contrast to the generally weak results obtained from community based cohorts, results from the prospective studies based on patients with CAD [9--], systemic lupus erythematosus [38] or renal failure [39] [40] [41] demonstrate that high tHcy is a very strong predictor of mortality or CVD-related complicarions. On the other hand, the tHey level does not predict, or only weakly predicts, progression of atherosclerosis or restenosis after PTCA [42, 43] .
Prospective studies
Overall, the prospective studies indicate that an elevated tHey level is a strong risk factor for CVD events in high risk populations, but a much weaker predictor of CVD events in presumably healthy individuals.
Total homocysteine as a cause or as an indicator of vascular disease?
Total homocysteine and the cardiovascular disease risk profile An elevated tHey level fulfills most of the defined criteria of causality, such as consistency, strength, temporality, and biological plausibility [44] . However, an elevated tHcy level is influenced by and shows a remarkable relation to several CVD risk factors [45] . Women have lower tHey levels than men, and tHcy increases with age and after menopause [7--,45] . Physical activity and a diet rich in fruit and vegetables are associated with a low plasma tHey, whereas smoking and caffeinated coffee increase the tHcy level [46,4r-] that they had overall favourable levels of the conventional CVD risk factors but their tHcy was high [52] . Similarly, 95 CAD patients with a low risk profile were found to have tHcy levels equal to those of matched control individuals [53] . These data, together with reports of MTHFR genotypes in CVD patients, some negative prospective studies and the relations between tHcy and other risk factors, have raised the question of whether an elevated tHcy is just an epiphenomenon reflecting the overall CVD risk [23--].
Homocystinuria
The case of homocystinuria brings strong support to the homocysteine theory. These inborn errors of metabolism are caused by cystathionine~-synthase deficiency, severe MTHFR deficiency or defects in intracellular cobalamin metabolism. Irrespective of the site of defect, these patients have a high incidence of vascular occlusive disease. Moreover, intervention with tHey lowering vitamins markedly reduces the risk of a fatal thromboembolic event [1].
The question has been raised as to whether high tHey alone is sufficient for development of CVD. In Israeli homocystinurics, Mandel et 01. [54] reported that thromboembolic events occurred only in patients with the factor V Leiden mutation. The possibility of an interactive phenomenon is supported by the finding of increased risk of venous thrombosis in hyperhomocysteinemic individuals with the factor V Leiden mutation [31, 55, 56] , but such an interaction has been questioned [57, 58] . A recent study [59] found the Leiden mutation in only one out of six homocystinuria individuals with thrombotic events, but a remarkably high prevalence (50%) of the TT MTHFR genotype. This suggests that a combination of genetic defects renders these individuals susceptible to vascular events.
In 1997, Wilcken and Wilcken published their results on the follow-up of 40 homocystinuria patients [60--] . Overall, there was an estimated 90% reduction in CVD events in the 32 individuals receiving effective homocysteine lowering therapy. Even among the 15 pyridoxine nonresponsive individuals with a mean tHcy of approximately 100/1mo1/l, no events were observed. Except for high tHey, the CVD risk profile is presumably low in these young individuals. The data indicate that elevated tHey causes disease, but in the absence of other risk factors, even a very high tHey level seems relatively harmless, emphasizing the multifactorial genesis of CVD.
Mechanisms of action
To date, there is no unifying hypothesis for the vascular effects of homocysteine, but proposed mechanisms include promotion of platelet activation, hypercoagulability, increased smooth muscle cell proliferation, cytotoxicity, stimulation of LDL oxidation and endothelial dysfunction [61,62,63--] . A recent study indicated that homocysteine-mediated responses on vascular smooth muscle cells are coupled to diacylglycerol-dependent protein kinase C activation via the N-methyl-o-aspartate receptor [64-] . Literature on mechanisms of action has been critically reviewed by Lentz [63--] .
Most mechanistic studies are carried out in vitro. The relevance of some of these studies to the development of vascular occlusion in vivo should be questioned because high homocysteine concentrations (in the millimolar range) are often used, similar effects can be obtained by other thiols [63--] and the in-vitro model systems usually do not reflect the disulfide exchange and redox reactions that take place in vivo [65] . Furthermore, the in-vitro data frequently do not explain the vascular pathology associated with hyperhomocysteinemia, in particular because homocystinuria and moderate hyperhomocysteinemia are associated with both venous and arterial occlusive disease [7--] whereas specific platelet or clotting abnormalities cause vascular lesions preferentially at either the venous or the arterial side [66] . Finally, plaque formation and atheroma are attributed to hypercholesterolemia and increased LDL oxidation, but are rarely observed in patients with homocystinuria [1, 62] .
A mechanism involving endothelial dysfunction seems attractive because it is relevant for both arterial and venous occlusion, and has been found in hyperhomocysteinemic patients in vivo [62,63--] . In 1976, Harker et al. [67] reported that endothelial desquamation occurs in baboons infused with Hcy. Endothelial lesions or increased circulating endothelial cells have also been observed in animal models [68, 69] and in healthy individuals receiving a standard methionine load [70-] . Notably, impaired endothelial-dependent vasodilatation (EVD) has recently been demonstrated in vivo in patients with homocystinuria [71] , transiently following methionine loading [72--,73] and in moderate hyperhomocysteinemia [74, 75] . Folate supplementation improves EVD both in hyperhomocysteinemic [76] and hypercholesterolemic individuals [77] , but not in hyperhomocysteinemic monkeys [78, 79] . No relationship between tHey and EVD was observed in renal failure patients [80] or in healthy individuals with chronic high methionine intake [81] . Conceivably, various experimental techniques may give different results, adaptive processes may exist, and the disease may modify the EVD response.
Elevated tHey may affect EVD by forming an S-nitrosohomocysteine adduct, which itself is a potent vasodilator. Nitric oxide may also be regarded as a homocysteine scavenger, and when depleted, free homocysteine can exert its toxic effect on the vascular endothelium as well as the smooth muscle cells [63--] . In addition, the prooxidant effects of high homocysteine levels may inhibit formation or enhance degradation of nitric oxide [61] . This idea is now supported by two studies that have shown that the effect of homocysteine on EVD can be prevented by vitamin C [82-] .
Perspectives
Findings during the past year have both challenged and refined the concept of tHey as a risk factor. Clinical trials with homocysteine reducing therapy are now required. The beneficial effects of such therapy are indicated by the observations that a high intake of folate or vitamin B6 is associated with lower CVD risk [83, 84] , and may delay the progression of atherosclerosis [85, 86] .
Different strategies for intervention have been proposed, but all studies currently in progress include folic acid. A daily supplement of 0.5 mg folic acid per day is expected to reduce plasma tHey by approximately 25%, and the reduction is largest in individuals with high tHey levels [87-] . A lower folic acid dose may be equally effective [88] . Overall, vitamin B12 will probably only lead to a small additional tHey reduction [87-] , but should be included because it may protect against undiscovered vitamin B12 deficiency. Vitamin B6 does not affect fasting tHey levels [7--], but may lower post-load tHey levels and have a cardioprotective effect unrelated to tHey [35-,89] .
Conclusion
The case of homocystinuria strongly suggests that severely elevated tHey levels are a causal risk factor for thromboembolic events, which can be prevented by homocysteine reducing therapy.
Recent studies suggest that moderate hyperhomocysteinemia enhances the effect of other risk factors and that it is more strongly associated with thrombosis or acute complications of CVD than with the slowly developing atherosclerotic process.
In the absence of other risk factors, moderate hyperhomocysteinemia seems to cause little harm, but it may promote CVD and the effects of coexisting risk factors.
The mechanism by which elevated homocysteine exerts its vascular effect is still unclear, but increasing evidence suggests that it interferes with normal endothelial function and impairs the nitric oxide-dependent vasodilatory response.
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